Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Study on the Course of Plasma Glutamine Levels During Critical Illness

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02310035
Recruitment Status : Completed
First Posted : December 5, 2014
Last Update Posted : May 13, 2015
Sponsor:
Information provided by (Responsible Party):
Matty Koopmans, Medical Centre Leeuwarden

Brief Summary:
Blood sampled for standard evaluation will be used for determination of plasma glutamine by Bioprofile Flex Glutamine Sensor at ICU admission

Condition or disease
Glutamine Levels

Detailed Description:

All patients who are admitted to the ICU after elective surgery and non-elective admissions. In both groups a total of 80 patients will be included.

(In the trials we mentioned in the introduction 80, 174 and 66 patients were included. In the study performed by Oudemans-van Straaten a decent distribution between lower and higher levels of glutamine was achieved in 80 non-elective patients.) Exclusion criteria are patients younger then 18 years and patients who need total parenteral nutrition (TPN).

The patients will receive standard care during their treatment on the ICU. Blood sampled for standard evaluation will be used for determination of plasma glutamine by Bioprofile Flex Glutamine Sensor at ICU admission. Hereafter plasma glutamine will be measured daily, a plasma sample will be taken from a standard evaluation blood sample at 6.00 am during admission on the ICU.

Layout table for study information
Study Type : Observational
Actual Enrollment : 178 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational Study on the Course of Plasma Glutamine Levels During Critial Illness
Study Start Date : April 2014
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014



Primary Outcome Measures :
  1. glutamine in serum [ Time Frame: from admission up to 8 days ]
    glutamine level at admission and during ICU stay daily



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients who are admitted to the ICU after elective surgery and non-elective admissions
Criteria

Inclusion Criteria:

  • all patients admitted to the ICU

Exclusion Criteria:

  • younger then 18 years and patients who need total parenteral nutrition

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02310035


Locations
Layout table for location information
Netherlands
Medical Centre Leeuwarden
Leeuwarden, Netherlands, 8934 AD
Sponsors and Collaborators
Medical Centre Leeuwarden
Investigators
Layout table for investigator information
Principal Investigator: Matty Koopmans, MSc Medical Centre Leeuwarden
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Matty Koopmans, MSc, Medical Centre Leeuwarden
ClinicalTrials.gov Identifier: NCT02310035    
Other Study ID Numbers: nWMO48
First Posted: December 5, 2014    Key Record Dates
Last Update Posted: May 13, 2015
Last Verified: May 2015